This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-12 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Of the twelve independent councillors, seven sit with the Green Party as the "Durham County Council Independent Group", two form the "Spennymoor and Tudhoe Independent Group", and the other three are not aligned to any group. After two Reform UK councillors stepped down, one of the seats was taken by the Lib Dems in a by-election in July. The other seat remained vacant until a by-election on 7 August that was won by Reform UK. The next full council elections are due in 2029.
The climate of Colombia is characterized for being tropical presenting variations within six natural regions and depending on the altitude, temperature, humidity, winds and rainfall. Colombia has a diverse range of climate zones, including tropical rainforests, savannas, steppes, deserts and mountain climates. Mountain climate is one of the unique features of the Andes and other high altitude reliefs where climate is determined by elevation. Below 1,000 meters (3,281 ft) in elevation is the warm altitudinal zone, where temperatures are above 24 °C (75.2 °F). About 82.5% of the country's total area lies in the warm altitudinal zone. The temperate climate altitudinal zone located between 1,001 and 2,000 meters (3,284 and 6,562 ft) is characterized for presenting an average temperature ranging between 17 and 24 °C (62.6 and 75.2 °F). The cold climate is present between 2,001 and 3,000 meters (6,565 and 9,843 ft) and the temperatures vary between 12 and 17 °C (53.6 and 62.6 °F). Beyond lies the alpine conditions of the forested zone and then the treeless grasslands of the páramos. Above 4,000 meters (13,123 ft), where temperatures are below freezing, the climate is glacial, a zone of permanent snow and ice.
Heinz bodies (also referred to as "Heinz-Ehrlich bodies") are inclusions within red blood cells composed of denatured hemoglobin. They are not visible with routine blood staining techniques, but can be seen with supravital staining. The presence of Heinz bodies represents damage to hemoglobin and is classically observed in G6PD deficiency, a genetic disorder that causes hemolytic anemia. In veterinary medicine, Heinz bodies may be seen following the consumption of foods containing thiosulfate and propylene glycol compounds by cats, dogs and certain primates.
== Side effects == Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear. A new wave of fentanyl analogues and associated deaths began in around 2014 in the US, and have continued to grow in prevalence; especially since 2016 these drugs have been responsible for hundreds of overdose deaths every week.
Sources: en.wikipedia.org
Sitagliptin was approved by the US Food and Drug Administration (FDA) in October 2006, and is sold under the brand name Januvia. In April 2007, the FDA approved an oral combination of sitagliptin/metformin sold under the brand name Janumet. In October 2011, the FDA approved an oral combination of sitagliptin/simvastatin sold under the brand name Juvisync. The extended release version of sitagliptin/metformin was approved in February 2012.
The Chinese People's Armed Police Coast Guard Bureau, also abbreviated as China Coast Guard is the agency for maritime search and rescue and law enforcement in the territorial waters of the People's Republic of China. The China Coast Guard was formerly the maritime branch of the People's Armed Police (PAP) Border Security Force under the Ministry of Public Security until 2013. In March 2013, China announced it would form a unified Coast Guard commanded by the State Oceanic Administration. This renewed Coast Guard has been in operation since July 2013. As of 1 July 2018, the China Coast Guard was transferred from civilian control of the State Council and the State Oceanic Administration, to the People's Armed Police, ultimately placing it under the command of the Central Military Commission (CMC). According to Joel Wuthnow of the Institute for National Strategic Studies, the Coast Guard Command within the People's Armed Police possibly is of Corps Leader Grade, led by a Commandant who usually holds the rank of major general. In June 2018, China Coast Guard was granted maritime rights and law enforcement akin civilian law enforcement agencies in order to carry out contrast of illegal activities, keep peace and order, as well as safeguarding security at sea, when performing duties related to the use of marine resources, protection of marine environment, regulation of fishery, and anti-smuggling. There are currently 3 regional bureaus:
Blood alcohol content (BAC), also known as blood alcohol concentration or blood alcohol level, is the concentration of alcohol in a person's blood, measured for legal or medical purposes. BAC is expressed as the mass of alcohol per unit volume of blood. In the United States and many other countries, it is commonly reported as a percentage, such as 0.08% (equivalent to 0.8 g/L). Legal limits for driving vary by country, ranging from zero tolerance policies to 0.08%. Levels above 0.40% (4 g/L) may be fatal.
Sources: en.wikipedia.org
== Revenue == The online healthcare startup has more than tripled its $520 million valuation following a AU$50 million raise in April 2023. It is reported that Eucalyptus currently has an annual revenue run-rate (ARR) upward of US$450 million and delivers quarterly triple-digit year-on-year ARR growth in 2025. The business is not yet profitable. In the 2024 financial year, it posted an AU$15.2 million after-tax loss.
Alpha-synuclein (aSyn) is a protein that in humans is encoded by the SNCA gene. It is a neuronal protein involved in the regulation of synaptic vesicle trafficking and the release of neurotransmitters. Alpha-synuclein is abundant in the brain, with smaller amounts present in the heart, muscles, and other tissues. Within the brain, it is primarily localized to the axon terminals of presynaptic neurons. There, it interacts with phospholipids and other proteins. Presynaptic terminals release neurotransmitters from specialized compartments called synaptic vesicles, a process essential for neuronal communication and normal brain function. In Parkinson's disease and related synucleinopathies, abnormal, insoluble forms of alpha-synuclein accumulate within neurons as inclusions known as Lewy bodies. Mutations in the SNCA gene are linked to familial forms of Parkinson's disease. During the process of seeded nucleation, alpha-synuclein adopts a cross-beta sheet structure characteristic of amyloid fibrils. The human alpha-synuclein protein consists of 140 amino acids. A fragment of alpha-synuclein, known as the non-amyloid beta component (NAC) of Alzheimer's disease amyloid, was initially isolated from an amyloid-rich brain fraction and shown to derive from a precursor protein named NACP. NACP was subsequently identified as the human homologue of synuclein from the electric ray genus Torpedo, leading to its renaming as human alpha-synuclein.
=== June === 8 June – Police in Roraima rescue 108 Cuban migrants attempting to enter the country from Guyana and arrest five suspected human traffickers. 11 June–19 July – Brazil participates at the 2026 FIFA World Cup 13 June – A 21-year-old woman dies after two rope jumping instructors throw her from a bridge in Limeira without harnessing her to safety equipment. 14 June – Six people, including American musician Oliver Tree, are killed when two helicopters collide over Rio de Janeiro. 16 June – The Supreme Federal Court sentences Eduardo Bolsonaro to four years and two months' imprisonment for trying to involve the United States in the trial of his father, former president Jair Bolsonaro, over the 2022–2023 Brazilian coup plot. Twenty-five people, including 18 Venezuelan nationals, are arrested in Roraima as part of an operation against the Tren de Aragua.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.